Global Embolotherapy Market

Embolotherapy Comprehensive Study by Type (Embolic Agents, Microspheres, Embolic Coils (Detachable Coils, Pushable Coils), Liquid Embolic Agents, Embolic Plug Systems, Detachable Balloons, Support Devices, Microcatheters, Guidewires), (), Indication (Cancer, Liver Cancer, Kidney Cancer, Other Cancers, Peripheral Vascular Diseases, Neurological Diseases, Cerebral Aneurysm, Cerebral Arteriovenous Malformations and Fistulas, Gastrointestinal Disorders, Urological and Nephrological Disorders), Procedure (Transcatheter Arterial Embolization, Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy, Transarterial Chemoembolization), End User (Hospitals and Clinics, Ambulatory Surgical Centers, Other End Users) Players and Region - Global Market Outlook to 2030

Embolotherapy Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Embolotherapy
Embolotherapy is a type of endovascular treatment that aims to occlude abnormal blood vessels in order to control bleeding, close fistulae or arteriovenous malformations, devascularise organs, reduce tumors, and much more. To achieve blocking, embolotherapy performs minimally-invasive methods and several embolic agents, such as gel foam, coils, balloons, and angiographic catheters to reach exact and significant results. As the field covers such a wide range of treatment possibilities, from recognized therapies such as TACE, UFE, and venous embolization, to some of the less commonly known applications such as hemorrhoid and arthritis embolization, it continues to advance in order to become more precise, more evidence-based and even more impactful in the years to come which is boosting the growth of the market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


In the embolotherapy market, it has been observed that most of the companies are upgrading or introducing innovative products. They rely on strategies such as mergers & acquisitions, product development, geographical expansion, technological innovation, and sourcing strategies to enhance their market share. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Embolotherapy market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Boston Scientific Corporation (United States), Merit Medical Systems (United States), Terumo Corporation (Japan), Medtronic plc (Ireland), Johnson & Johnson (United States), Stryker Corporation (United States), BTG plc (United Kingdom), Penumbra, Inc. (United States), Cook Medical (United States), Abbott Laboratories (United States), Acandis GmbH (Germany) and BALT Extrusion (France) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sirtex Medical Limited (Australia), Kaneka Corporation (Japan) and Meril Life Sciences Pvt. Ltd. (India).

Segmentation Overview
AMA Research has segmented the market of Global Embolotherapy market by Type (Embolic Agents, Microspheres, Embolic Coils (Detachable Coils, Pushable Coils), Liquid Embolic Agents, Embolic Plug Systems, Detachable Balloons, Support Devices, Microcatheters and Guidewires) and Region.



On the basis of geography, the market of Embolotherapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by , the sub-segment i.e. will boost the Embolotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indication, the sub-segment i.e. Cancer will boost the Embolotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Procedure, the sub-segment i.e. Transcatheter Arterial Embolization will boost the Embolotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals and Clinics will boost the Embolotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Investments and Technological Advancements in Embolotherapy Devices

Market Growth Drivers:
Rising Incidences of Peripheral Vascular Diseases, Liver Cancer, and Strokes and Increasing Preference for Minimally Invasive Procedures

Challenges:
Dearth of Skilled Surgeons

Restraints:
Availability of Alternative Therapies and Unfavorable Regulatory Scenario

Opportunities:
Increasing Applications of Embolization Devices and Growth Opportunities in Emerging Markets

Market Leaders and their expansionary development strategies
In September 2023, Balt Extrusion announces a collaboration with medical device startup Embozoid to develop advanced embolization coils with enhanced biocompatibility and mechanical properties. This collaboration aims to leverage Balt Extrusion's expertise in polymer extrusion with Embozoid's innovative coil design to create next-generation embolization devices.
In August 2023, C&S Medical, Inc. announces the launch of its new EmboCoil embolization coils in Europe. These coils are designed for the embolization of peripheral arteries and veins, and offer a variety of features to improve deliverability and visibility.


Key Target Audience
Embolotherapy Devices Manufacturers, Embolotherapy Service Providers, Embolotherapy Industry Association, Research and Development Institutes, Potential Investors, Regulatory Bodies, Hospitals and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Embolic Agents
  • Microspheres
  • Embolic Coils (Detachable Coils, Pushable Coils)
  • Liquid Embolic Agents
  • Embolic Plug Systems
  • Detachable Balloons
  • Support Devices
  • Microcatheters
  • Guidewires
By Indication
  • Cancer
  • Liver Cancer
  • Kidney Cancer
  • Other Cancers
  • Peripheral Vascular Diseases
  • Neurological Diseases
  • Cerebral Aneurysm
  • Cerebral Arteriovenous Malformations and Fistulas
  • Gastrointestinal Disorders
  • Urological and Nephrological Disorders

By Procedure
  • Transcatheter Arterial Embolization
  • Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
  • Transarterial Chemoembolization

By End User
  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Other End Users

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidences of Peripheral Vascular Diseases, Liver Cancer, and Strokes
      • 3.2.2. Increasing Preference for Minimally Invasive Procedures
    • 3.3. Market Challenges
      • 3.3.1. Dearth of Skilled Surgeons
    • 3.4. Market Trends
      • 3.4.1. Increasing Investments and Technological Advancements in Embolotherapy Devices
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Embolotherapy, by Type, , Indication, Procedure, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Embolotherapy (Value)
      • 5.2.1. Global Embolotherapy by: Type (Value)
        • 5.2.1.1. Embolic Agents
        • 5.2.1.2. Microspheres
        • 5.2.1.3. Embolic Coils (Detachable Coils, Pushable Coils)
        • 5.2.1.4. Liquid Embolic Agents
        • 5.2.1.5. Embolic Plug Systems
        • 5.2.1.6. Detachable Balloons
        • 5.2.1.7. Support Devices
        • 5.2.1.8. Microcatheters
        • 5.2.1.9. Guidewires
      • 5.2.2. Global Embolotherapy by: Indication (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Liver Cancer
        • 5.2.2.3. Kidney Cancer
        • 5.2.2.4. Other Cancers
        • 5.2.2.5. Peripheral Vascular Diseases
        • 5.2.2.6. Neurological Diseases
        • 5.2.2.7. Cerebral Aneurysm
        • 5.2.2.8. Cerebral Arteriovenous Malformations and Fistulas
        • 5.2.2.9. Gastrointestinal Disorders
        • 5.2.2.10. Urological and Nephrological Disorders
      • 5.2.3. Global Embolotherapy by: Procedure (Value)
        • 5.2.3.1. Transcatheter Arterial Embolization
        • 5.2.3.2. Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
        • 5.2.3.3. Transarterial Chemoembolization
      • 5.2.4. Global Embolotherapy by: End User (Value)
        • 5.2.4.1. Hospitals and Clinics
        • 5.2.4.2. Ambulatory Surgical Centers
        • 5.2.4.3. Other End Users
      • 5.2.5. Global Embolotherapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Embolotherapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Boston Scientific Corporation (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merit Medical Systems (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Terumo Corporation (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Medtronic plc (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Stryker Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. BTG plc (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Penumbra, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cook Medical (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Abbott Laboratories (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Acandis GmbH (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. BALT Extrusion (France)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Embolotherapy Sale, by Type, , Indication, Procedure, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Embolotherapy (Value)
      • 7.2.1. Global Embolotherapy by: Type (Value)
        • 7.2.1.1. Embolic Agents
        • 7.2.1.2. Microspheres
        • 7.2.1.3. Embolic Coils (Detachable Coils, Pushable Coils)
        • 7.2.1.4. Liquid Embolic Agents
        • 7.2.1.5. Embolic Plug Systems
        • 7.2.1.6. Detachable Balloons
        • 7.2.1.7. Support Devices
        • 7.2.1.8. Microcatheters
        • 7.2.1.9. Guidewires
      • 7.2.2. Global Embolotherapy by: Indication (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Liver Cancer
        • 7.2.2.3. Kidney Cancer
        • 7.2.2.4. Other Cancers
        • 7.2.2.5. Peripheral Vascular Diseases
        • 7.2.2.6. Neurological Diseases
        • 7.2.2.7. Cerebral Aneurysm
        • 7.2.2.8. Cerebral Arteriovenous Malformations and Fistulas
        • 7.2.2.9. Gastrointestinal Disorders
        • 7.2.2.10. Urological and Nephrological Disorders
      • 7.2.3. Global Embolotherapy by: Procedure (Value)
        • 7.2.3.1. Transcatheter Arterial Embolization
        • 7.2.3.2. Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
        • 7.2.3.3. Transarterial Chemoembolization
      • 7.2.4. Global Embolotherapy by: End User (Value)
        • 7.2.4.1. Hospitals and Clinics
        • 7.2.4.2. Ambulatory Surgical Centers
        • 7.2.4.3. Other End Users
      • 7.2.5. Global Embolotherapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Embolotherapy: by Type(USD Million)
  • Table 2. Embolotherapy Embolic Agents , by Region USD Million (2018-2023)
  • Table 3. Embolotherapy Microspheres , by Region USD Million (2018-2023)
  • Table 4. Embolotherapy Embolic Coils (Detachable Coils, Pushable Coils) , by Region USD Million (2018-2023)
  • Table 5. Embolotherapy Liquid Embolic Agents , by Region USD Million (2018-2023)
  • Table 6. Embolotherapy Embolic Plug Systems , by Region USD Million (2018-2023)
  • Table 7. Embolotherapy Detachable Balloons , by Region USD Million (2018-2023)
  • Table 8. Embolotherapy Support Devices , by Region USD Million (2018-2023)
  • Table 9. Embolotherapy Microcatheters , by Region USD Million (2018-2023)
  • Table 10. Embolotherapy Guidewires , by Region USD Million (2018-2023)
  • Table 11. Embolotherapy: by Indication(USD Million)
  • Table 12. Embolotherapy Cancer , by Region USD Million (2018-2023)
  • Table 13. Embolotherapy Liver Cancer , by Region USD Million (2018-2023)
  • Table 14. Embolotherapy Kidney Cancer , by Region USD Million (2018-2023)
  • Table 15. Embolotherapy Other Cancers , by Region USD Million (2018-2023)
  • Table 16. Embolotherapy Peripheral Vascular Diseases , by Region USD Million (2018-2023)
  • Table 17. Embolotherapy Neurological Diseases , by Region USD Million (2018-2023)
  • Table 18. Embolotherapy Cerebral Aneurysm , by Region USD Million (2018-2023)
  • Table 19. Embolotherapy Cerebral Arteriovenous Malformations and Fistulas , by Region USD Million (2018-2023)
  • Table 20. Embolotherapy Gastrointestinal Disorders , by Region USD Million (2018-2023)
  • Table 21. Embolotherapy Urological and Nephrological Disorders , by Region USD Million (2018-2023)
  • Table 22. Embolotherapy: by Procedure(USD Million)
  • Table 23. Embolotherapy Transcatheter Arterial Embolization , by Region USD Million (2018-2023)
  • Table 24. Embolotherapy Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy , by Region USD Million (2018-2023)
  • Table 25. Embolotherapy Transarterial Chemoembolization , by Region USD Million (2018-2023)
  • Table 26. Embolotherapy: by End User(USD Million)
  • Table 27. Embolotherapy Hospitals and Clinics , by Region USD Million (2018-2023)
  • Table 28. Embolotherapy Ambulatory Surgical Centers , by Region USD Million (2018-2023)
  • Table 29. Embolotherapy Other End Users , by Region USD Million (2018-2023)
  • Table 30. South America Embolotherapy, by Country USD Million (2018-2023)
  • Table 31. South America Embolotherapy, by Type USD Million (2018-2023)
  • Table 32. South America Embolotherapy, by Indication USD Million (2018-2023)
  • Table 33. South America Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 34. South America Embolotherapy, by End User USD Million (2018-2023)
  • Table 35. Brazil Embolotherapy, by Type USD Million (2018-2023)
  • Table 36. Brazil Embolotherapy, by Indication USD Million (2018-2023)
  • Table 37. Brazil Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 38. Brazil Embolotherapy, by End User USD Million (2018-2023)
  • Table 39. Argentina Embolotherapy, by Type USD Million (2018-2023)
  • Table 40. Argentina Embolotherapy, by Indication USD Million (2018-2023)
  • Table 41. Argentina Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 42. Argentina Embolotherapy, by End User USD Million (2018-2023)
  • Table 43. Rest of South America Embolotherapy, by Type USD Million (2018-2023)
  • Table 44. Rest of South America Embolotherapy, by Indication USD Million (2018-2023)
  • Table 45. Rest of South America Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 46. Rest of South America Embolotherapy, by End User USD Million (2018-2023)
  • Table 47. Asia Pacific Embolotherapy, by Country USD Million (2018-2023)
  • Table 48. Asia Pacific Embolotherapy, by Type USD Million (2018-2023)
  • Table 49. Asia Pacific Embolotherapy, by Indication USD Million (2018-2023)
  • Table 50. Asia Pacific Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 51. Asia Pacific Embolotherapy, by End User USD Million (2018-2023)
  • Table 52. China Embolotherapy, by Type USD Million (2018-2023)
  • Table 53. China Embolotherapy, by Indication USD Million (2018-2023)
  • Table 54. China Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 55. China Embolotherapy, by End User USD Million (2018-2023)
  • Table 56. Japan Embolotherapy, by Type USD Million (2018-2023)
  • Table 57. Japan Embolotherapy, by Indication USD Million (2018-2023)
  • Table 58. Japan Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 59. Japan Embolotherapy, by End User USD Million (2018-2023)
  • Table 60. India Embolotherapy, by Type USD Million (2018-2023)
  • Table 61. India Embolotherapy, by Indication USD Million (2018-2023)
  • Table 62. India Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 63. India Embolotherapy, by End User USD Million (2018-2023)
  • Table 64. South Korea Embolotherapy, by Type USD Million (2018-2023)
  • Table 65. South Korea Embolotherapy, by Indication USD Million (2018-2023)
  • Table 66. South Korea Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 67. South Korea Embolotherapy, by End User USD Million (2018-2023)
  • Table 68. Taiwan Embolotherapy, by Type USD Million (2018-2023)
  • Table 69. Taiwan Embolotherapy, by Indication USD Million (2018-2023)
  • Table 70. Taiwan Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 71. Taiwan Embolotherapy, by End User USD Million (2018-2023)
  • Table 72. Australia Embolotherapy, by Type USD Million (2018-2023)
  • Table 73. Australia Embolotherapy, by Indication USD Million (2018-2023)
  • Table 74. Australia Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 75. Australia Embolotherapy, by End User USD Million (2018-2023)
  • Table 76. Rest of Asia-Pacific Embolotherapy, by Type USD Million (2018-2023)
  • Table 77. Rest of Asia-Pacific Embolotherapy, by Indication USD Million (2018-2023)
  • Table 78. Rest of Asia-Pacific Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 79. Rest of Asia-Pacific Embolotherapy, by End User USD Million (2018-2023)
  • Table 80. Europe Embolotherapy, by Country USD Million (2018-2023)
  • Table 81. Europe Embolotherapy, by Type USD Million (2018-2023)
  • Table 82. Europe Embolotherapy, by Indication USD Million (2018-2023)
  • Table 83. Europe Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 84. Europe Embolotherapy, by End User USD Million (2018-2023)
  • Table 85. Germany Embolotherapy, by Type USD Million (2018-2023)
  • Table 86. Germany Embolotherapy, by Indication USD Million (2018-2023)
  • Table 87. Germany Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 88. Germany Embolotherapy, by End User USD Million (2018-2023)
  • Table 89. France Embolotherapy, by Type USD Million (2018-2023)
  • Table 90. France Embolotherapy, by Indication USD Million (2018-2023)
  • Table 91. France Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 92. France Embolotherapy, by End User USD Million (2018-2023)
  • Table 93. Italy Embolotherapy, by Type USD Million (2018-2023)
  • Table 94. Italy Embolotherapy, by Indication USD Million (2018-2023)
  • Table 95. Italy Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 96. Italy Embolotherapy, by End User USD Million (2018-2023)
  • Table 97. United Kingdom Embolotherapy, by Type USD Million (2018-2023)
  • Table 98. United Kingdom Embolotherapy, by Indication USD Million (2018-2023)
  • Table 99. United Kingdom Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 100. United Kingdom Embolotherapy, by End User USD Million (2018-2023)
  • Table 101. Netherlands Embolotherapy, by Type USD Million (2018-2023)
  • Table 102. Netherlands Embolotherapy, by Indication USD Million (2018-2023)
  • Table 103. Netherlands Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 104. Netherlands Embolotherapy, by End User USD Million (2018-2023)
  • Table 105. Rest of Europe Embolotherapy, by Type USD Million (2018-2023)
  • Table 106. Rest of Europe Embolotherapy, by Indication USD Million (2018-2023)
  • Table 107. Rest of Europe Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 108. Rest of Europe Embolotherapy, by End User USD Million (2018-2023)
  • Table 109. MEA Embolotherapy, by Country USD Million (2018-2023)
  • Table 110. MEA Embolotherapy, by Type USD Million (2018-2023)
  • Table 111. MEA Embolotherapy, by Indication USD Million (2018-2023)
  • Table 112. MEA Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 113. MEA Embolotherapy, by End User USD Million (2018-2023)
  • Table 114. Middle East Embolotherapy, by Type USD Million (2018-2023)
  • Table 115. Middle East Embolotherapy, by Indication USD Million (2018-2023)
  • Table 116. Middle East Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 117. Middle East Embolotherapy, by End User USD Million (2018-2023)
  • Table 118. Africa Embolotherapy, by Type USD Million (2018-2023)
  • Table 119. Africa Embolotherapy, by Indication USD Million (2018-2023)
  • Table 120. Africa Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 121. Africa Embolotherapy, by End User USD Million (2018-2023)
  • Table 122. North America Embolotherapy, by Country USD Million (2018-2023)
  • Table 123. North America Embolotherapy, by Type USD Million (2018-2023)
  • Table 124. North America Embolotherapy, by Indication USD Million (2018-2023)
  • Table 125. North America Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 126. North America Embolotherapy, by End User USD Million (2018-2023)
  • Table 127. United States Embolotherapy, by Type USD Million (2018-2023)
  • Table 128. United States Embolotherapy, by Indication USD Million (2018-2023)
  • Table 129. United States Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 130. United States Embolotherapy, by End User USD Million (2018-2023)
  • Table 131. Canada Embolotherapy, by Type USD Million (2018-2023)
  • Table 132. Canada Embolotherapy, by Indication USD Million (2018-2023)
  • Table 133. Canada Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 134. Canada Embolotherapy, by End User USD Million (2018-2023)
  • Table 135. Mexico Embolotherapy, by Type USD Million (2018-2023)
  • Table 136. Mexico Embolotherapy, by Indication USD Million (2018-2023)
  • Table 137. Mexico Embolotherapy, by Procedure USD Million (2018-2023)
  • Table 138. Mexico Embolotherapy, by End User USD Million (2018-2023)
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Company Basic Information, Sales Area and Its Competitors
  • Table 148. Company Basic Information, Sales Area and Its Competitors
  • Table 149. Company Basic Information, Sales Area and Its Competitors
  • Table 150. Company Basic Information, Sales Area and Its Competitors
  • Table 151. Embolotherapy: by Type(USD Million)
  • Table 152. Embolotherapy Embolic Agents , by Region USD Million (2025-2030)
  • Table 153. Embolotherapy Microspheres , by Region USD Million (2025-2030)
  • Table 154. Embolotherapy Embolic Coils (Detachable Coils, Pushable Coils) , by Region USD Million (2025-2030)
  • Table 155. Embolotherapy Liquid Embolic Agents , by Region USD Million (2025-2030)
  • Table 156. Embolotherapy Embolic Plug Systems , by Region USD Million (2025-2030)
  • Table 157. Embolotherapy Detachable Balloons , by Region USD Million (2025-2030)
  • Table 158. Embolotherapy Support Devices , by Region USD Million (2025-2030)
  • Table 159. Embolotherapy Microcatheters , by Region USD Million (2025-2030)
  • Table 160. Embolotherapy Guidewires , by Region USD Million (2025-2030)
  • Table 161. Embolotherapy: by Indication(USD Million)
  • Table 162. Embolotherapy Cancer , by Region USD Million (2025-2030)
  • Table 163. Embolotherapy Liver Cancer , by Region USD Million (2025-2030)
  • Table 164. Embolotherapy Kidney Cancer , by Region USD Million (2025-2030)
  • Table 165. Embolotherapy Other Cancers , by Region USD Million (2025-2030)
  • Table 166. Embolotherapy Peripheral Vascular Diseases , by Region USD Million (2025-2030)
  • Table 167. Embolotherapy Neurological Diseases , by Region USD Million (2025-2030)
  • Table 168. Embolotherapy Cerebral Aneurysm , by Region USD Million (2025-2030)
  • Table 169. Embolotherapy Cerebral Arteriovenous Malformations and Fistulas , by Region USD Million (2025-2030)
  • Table 170. Embolotherapy Gastrointestinal Disorders , by Region USD Million (2025-2030)
  • Table 171. Embolotherapy Urological and Nephrological Disorders , by Region USD Million (2025-2030)
  • Table 172. Embolotherapy: by Procedure(USD Million)
  • Table 173. Embolotherapy Transcatheter Arterial Embolization , by Region USD Million (2025-2030)
  • Table 174. Embolotherapy Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy , by Region USD Million (2025-2030)
  • Table 175. Embolotherapy Transarterial Chemoembolization , by Region USD Million (2025-2030)
  • Table 176. Embolotherapy: by End User(USD Million)
  • Table 177. Embolotherapy Hospitals and Clinics , by Region USD Million (2025-2030)
  • Table 178. Embolotherapy Ambulatory Surgical Centers , by Region USD Million (2025-2030)
  • Table 179. Embolotherapy Other End Users , by Region USD Million (2025-2030)
  • Table 180. South America Embolotherapy, by Country USD Million (2025-2030)
  • Table 181. South America Embolotherapy, by Type USD Million (2025-2030)
  • Table 182. South America Embolotherapy, by Indication USD Million (2025-2030)
  • Table 183. South America Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 184. South America Embolotherapy, by End User USD Million (2025-2030)
  • Table 185. Brazil Embolotherapy, by Type USD Million (2025-2030)
  • Table 186. Brazil Embolotherapy, by Indication USD Million (2025-2030)
  • Table 187. Brazil Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 188. Brazil Embolotherapy, by End User USD Million (2025-2030)
  • Table 189. Argentina Embolotherapy, by Type USD Million (2025-2030)
  • Table 190. Argentina Embolotherapy, by Indication USD Million (2025-2030)
  • Table 191. Argentina Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 192. Argentina Embolotherapy, by End User USD Million (2025-2030)
  • Table 193. Rest of South America Embolotherapy, by Type USD Million (2025-2030)
  • Table 194. Rest of South America Embolotherapy, by Indication USD Million (2025-2030)
  • Table 195. Rest of South America Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 196. Rest of South America Embolotherapy, by End User USD Million (2025-2030)
  • Table 197. Asia Pacific Embolotherapy, by Country USD Million (2025-2030)
  • Table 198. Asia Pacific Embolotherapy, by Type USD Million (2025-2030)
  • Table 199. Asia Pacific Embolotherapy, by Indication USD Million (2025-2030)
  • Table 200. Asia Pacific Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 201. Asia Pacific Embolotherapy, by End User USD Million (2025-2030)
  • Table 202. China Embolotherapy, by Type USD Million (2025-2030)
  • Table 203. China Embolotherapy, by Indication USD Million (2025-2030)
  • Table 204. China Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 205. China Embolotherapy, by End User USD Million (2025-2030)
  • Table 206. Japan Embolotherapy, by Type USD Million (2025-2030)
  • Table 207. Japan Embolotherapy, by Indication USD Million (2025-2030)
  • Table 208. Japan Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 209. Japan Embolotherapy, by End User USD Million (2025-2030)
  • Table 210. India Embolotherapy, by Type USD Million (2025-2030)
  • Table 211. India Embolotherapy, by Indication USD Million (2025-2030)
  • Table 212. India Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 213. India Embolotherapy, by End User USD Million (2025-2030)
  • Table 214. South Korea Embolotherapy, by Type USD Million (2025-2030)
  • Table 215. South Korea Embolotherapy, by Indication USD Million (2025-2030)
  • Table 216. South Korea Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 217. South Korea Embolotherapy, by End User USD Million (2025-2030)
  • Table 218. Taiwan Embolotherapy, by Type USD Million (2025-2030)
  • Table 219. Taiwan Embolotherapy, by Indication USD Million (2025-2030)
  • Table 220. Taiwan Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 221. Taiwan Embolotherapy, by End User USD Million (2025-2030)
  • Table 222. Australia Embolotherapy, by Type USD Million (2025-2030)
  • Table 223. Australia Embolotherapy, by Indication USD Million (2025-2030)
  • Table 224. Australia Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 225. Australia Embolotherapy, by End User USD Million (2025-2030)
  • Table 226. Rest of Asia-Pacific Embolotherapy, by Type USD Million (2025-2030)
  • Table 227. Rest of Asia-Pacific Embolotherapy, by Indication USD Million (2025-2030)
  • Table 228. Rest of Asia-Pacific Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 229. Rest of Asia-Pacific Embolotherapy, by End User USD Million (2025-2030)
  • Table 230. Europe Embolotherapy, by Country USD Million (2025-2030)
  • Table 231. Europe Embolotherapy, by Type USD Million (2025-2030)
  • Table 232. Europe Embolotherapy, by Indication USD Million (2025-2030)
  • Table 233. Europe Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 234. Europe Embolotherapy, by End User USD Million (2025-2030)
  • Table 235. Germany Embolotherapy, by Type USD Million (2025-2030)
  • Table 236. Germany Embolotherapy, by Indication USD Million (2025-2030)
  • Table 237. Germany Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 238. Germany Embolotherapy, by End User USD Million (2025-2030)
  • Table 239. France Embolotherapy, by Type USD Million (2025-2030)
  • Table 240. France Embolotherapy, by Indication USD Million (2025-2030)
  • Table 241. France Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 242. France Embolotherapy, by End User USD Million (2025-2030)
  • Table 243. Italy Embolotherapy, by Type USD Million (2025-2030)
  • Table 244. Italy Embolotherapy, by Indication USD Million (2025-2030)
  • Table 245. Italy Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 246. Italy Embolotherapy, by End User USD Million (2025-2030)
  • Table 247. United Kingdom Embolotherapy, by Type USD Million (2025-2030)
  • Table 248. United Kingdom Embolotherapy, by Indication USD Million (2025-2030)
  • Table 249. United Kingdom Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 250. United Kingdom Embolotherapy, by End User USD Million (2025-2030)
  • Table 251. Netherlands Embolotherapy, by Type USD Million (2025-2030)
  • Table 252. Netherlands Embolotherapy, by Indication USD Million (2025-2030)
  • Table 253. Netherlands Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 254. Netherlands Embolotherapy, by End User USD Million (2025-2030)
  • Table 255. Rest of Europe Embolotherapy, by Type USD Million (2025-2030)
  • Table 256. Rest of Europe Embolotherapy, by Indication USD Million (2025-2030)
  • Table 257. Rest of Europe Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 258. Rest of Europe Embolotherapy, by End User USD Million (2025-2030)
  • Table 259. MEA Embolotherapy, by Country USD Million (2025-2030)
  • Table 260. MEA Embolotherapy, by Type USD Million (2025-2030)
  • Table 261. MEA Embolotherapy, by Indication USD Million (2025-2030)
  • Table 262. MEA Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 263. MEA Embolotherapy, by End User USD Million (2025-2030)
  • Table 264. Middle East Embolotherapy, by Type USD Million (2025-2030)
  • Table 265. Middle East Embolotherapy, by Indication USD Million (2025-2030)
  • Table 266. Middle East Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 267. Middle East Embolotherapy, by End User USD Million (2025-2030)
  • Table 268. Africa Embolotherapy, by Type USD Million (2025-2030)
  • Table 269. Africa Embolotherapy, by Indication USD Million (2025-2030)
  • Table 270. Africa Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 271. Africa Embolotherapy, by End User USD Million (2025-2030)
  • Table 272. North America Embolotherapy, by Country USD Million (2025-2030)
  • Table 273. North America Embolotherapy, by Type USD Million (2025-2030)
  • Table 274. North America Embolotherapy, by Indication USD Million (2025-2030)
  • Table 275. North America Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 276. North America Embolotherapy, by End User USD Million (2025-2030)
  • Table 277. United States Embolotherapy, by Type USD Million (2025-2030)
  • Table 278. United States Embolotherapy, by Indication USD Million (2025-2030)
  • Table 279. United States Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 280. United States Embolotherapy, by End User USD Million (2025-2030)
  • Table 281. Canada Embolotherapy, by Type USD Million (2025-2030)
  • Table 282. Canada Embolotherapy, by Indication USD Million (2025-2030)
  • Table 283. Canada Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 284. Canada Embolotherapy, by End User USD Million (2025-2030)
  • Table 285. Mexico Embolotherapy, by Type USD Million (2025-2030)
  • Table 286. Mexico Embolotherapy, by Indication USD Million (2025-2030)
  • Table 287. Mexico Embolotherapy, by Procedure USD Million (2025-2030)
  • Table 288. Mexico Embolotherapy, by End User USD Million (2025-2030)
  • Table 289. Research Programs/Design for This Report
  • Table 290. Key Data Information from Secondary Sources
  • Table 291. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Embolotherapy: by Type USD Million (2018-2023)
  • Figure 5. Global Embolotherapy: by Indication USD Million (2018-2023)
  • Figure 6. Global Embolotherapy: by Procedure USD Million (2018-2023)
  • Figure 7. Global Embolotherapy: by End User USD Million (2018-2023)
  • Figure 8. South America Embolotherapy Share (%), by Country
  • Figure 9. Asia Pacific Embolotherapy Share (%), by Country
  • Figure 10. Europe Embolotherapy Share (%), by Country
  • Figure 11. MEA Embolotherapy Share (%), by Country
  • Figure 12. North America Embolotherapy Share (%), by Country
  • Figure 13. Global Embolotherapy share by Players 2023 (%)
  • Figure 14. Global Embolotherapy share by Players (Top 3) 2023(%)
  • Figure 15. Global Embolotherapy share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 18. Boston Scientific Corporation (United States) Revenue: by Geography 2023
  • Figure 19. Merit Medical Systems (United States) Revenue, Net Income and Gross profit
  • Figure 20. Merit Medical Systems (United States) Revenue: by Geography 2023
  • Figure 21. Terumo Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 22. Terumo Corporation (Japan) Revenue: by Geography 2023
  • Figure 23. Medtronic plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 24. Medtronic plc (Ireland) Revenue: by Geography 2023
  • Figure 25. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 26. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 27. Stryker Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Stryker Corporation (United States) Revenue: by Geography 2023
  • Figure 29. BTG plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. BTG plc (United Kingdom) Revenue: by Geography 2023
  • Figure 31. Penumbra, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Penumbra, Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Cook Medical (United States) Revenue, Net Income and Gross profit
  • Figure 34. Cook Medical (United States) Revenue: by Geography 2023
  • Figure 35. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 36. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 37. Acandis GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 38. Acandis GmbH (Germany) Revenue: by Geography 2023
  • Figure 39. BALT Extrusion (France) Revenue, Net Income and Gross profit
  • Figure 40. BALT Extrusion (France) Revenue: by Geography 2023
  • Figure 41. Global Embolotherapy: by Type USD Million (2025-2030)
  • Figure 42. Global Embolotherapy: by Indication USD Million (2025-2030)
  • Figure 43. Global Embolotherapy: by Procedure USD Million (2025-2030)
  • Figure 44. Global Embolotherapy: by End User USD Million (2025-2030)
  • Figure 45. South America Embolotherapy Share (%), by Country
  • Figure 46. Asia Pacific Embolotherapy Share (%), by Country
  • Figure 47. Europe Embolotherapy Share (%), by Country
  • Figure 48. MEA Embolotherapy Share (%), by Country
  • Figure 49. North America Embolotherapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Boston Scientific Corporation (United States)
  • Merit Medical Systems (United States)
  • Terumo Corporation (Japan)
  • Medtronic plc (Ireland)
  • Johnson & Johnson (United States)
  • Stryker Corporation (United States)
  • BTG plc (United Kingdom)
  • Penumbra, Inc. (United States)
  • Cook Medical (United States)
  • Abbott Laboratories (United States)
  • Acandis GmbH (Germany)
  • BALT Extrusion (France)
Additional players considered in the study are as follows:
Sirtex Medical Limited (Australia) , Kaneka Corporation (Japan) , Meril Life Sciences Pvt. Ltd. (India)
Select User Access Type

Key Highlights of Report


Jan 2024 219 Pages 74 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Embolotherapy Market Quantitative research analysis
Global Embolotherapy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Boston Scientific Corporation (United States), Merit Medical Systems (United States), Terumo Corporation (Japan), Medtronic plc (Ireland), Johnson & Johnson (United States), Stryker Corporation (United States), BTG plc (United Kingdom), Penumbra, Inc. (United States), Cook Medical (United States), Abbott Laboratories (United States), Acandis GmbH (Germany) and BALT Extrusion (France) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Investments and Technological Advancements in Embolotherapy Devices" is seen as one of major influencing trends for Embolotherapy Market during projected period 2023-2030.
The Embolotherapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Embolotherapy Market Report?

Have a Query? Click Here

Other Related Reports

Plaque Psoriasis Treatment Comprehensive Study by Type (Topical Therapy, Phototherapy, Systemic Agents, Biologic Therapies), Application (Hospitals, Clinics, Others), Drug Class (TNF-α Inhibitor...
$ 3350
Cerebral Infarction Therapy Comprehensive Study by Type (Partial Anterior Circulation Infarct (PACI), Total Anterior Circulation Infarct (TACI), Posterior Circulation Infarct (POCI)), Application (Ho...
$ 3650
Smokeless Tobacco Treatment  Comprehensive Study by Type (Keratosis Treatment, Addiction Treatment, Disease Treatment), Application (Hospitals & Clinics, Academic & Research Organizations, Pharmacies...
$ 3750
Anaplastic Thyroid Cancer Comprehensive Study by Application (Hospitals, Clinics, Ambulatory Surgery Centers), Treatment (Surgery, Radiation Therapy, Chemotherapy, Other), Diagnosis (Imaging (Ultraso...
$ 3350
Behavioral Health Comprehensive Study by Type (Depression, Anxiety, Schizophrenia, Alcohol Use Disorders, Others), Service (Emergency Mental Health Services, Outpatient Counseling, Home-Based Treatme...
$ 3450
Quadrivalent Flu Vaccine Comprehensive Study by Type (Intramuscular Injection, Nasal Spray, Intradermal Shot), Application (Hospital, Clinic, Public Health Agency, Other), Age Group (Adults, Pediatri...
$ 3500